Homoharringtonine clinical trials
Homoharringtonine is named as an intervention in 17 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (5). The most-studied condition is Acute Myeloid Leukemia (AML).
Where Homoharringtonine is approved
All regulators →- 2 EU orphan designations, most recently for treatment of acute myeloid leukaemia (20 Oct 2004, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Homoharringtonine works
All drug targets →- T-cell acute lymphoblastic leukemiaPhase 3
- T-cell adult acute lymphocytic leukemiaPhase 3
- Acute lymphoblastic leukemiaPhase 3
- Acute myeloid leukemiaPhase 3
- Chronic myeloid leukemiaPhase 3
- Myelodysplastic syndromePhase 3
- LeukemiaPhase 2
- LymphomaPhase 2
- Mixed phenotype acute leukemiaPhase 2
- Myeloid leukemiaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL46286, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7454, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Homoharringtonine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Homoharringtonine
- ATC code
- L01XX40
- ChEMBL
- CHEMBL46286
- DrugBank
- DB04865
- PubChem CID
- 285033
- CAS number
- 26833-87-4
- FDA UNII
- 6FG8041S5B
- Wikidata
- Q7089373
- Wikipedia
- Omacetaxine mepesuccinate
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Homoharringtonine
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Homoharringtonine
19 conditionsAll 19 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia (AML) | 4 |
| AML | 3 |
| Acute Myeloid Leukemia | 3 |
| Lisaftoclax | 2 |
| AML, Adult | 1 |
| Acute T Lymphpblastic Leukemia/Lymphoma | 1 |
| ETP-ALL | 1 |
| Diffuse Large B-Cell Lymphoma | 1 |
| Relapsed Non-Hodgkin Lymphoma | 1 |
| Refractory Non-Hodgkin Lymphoma | 1 |
| Elderly Patients (60-75 Years) | 1 |
| Prostate CA | 1 |
| Acute Lymphoblastic Leukemia | 1 |
| Childhood Leukemia, Acute Lymphoblastic | 1 |
| T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | 1 |
| AML, Childhood | 1 |
| Prostate Cancer | 1 |
| Refractory | 1 |
| Relapsed | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 17 | 10 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Homoharringtonine trials
How many clinical trials are testing Homoharringtonine?
17 current trials in our China register name Homoharringtonine as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are Homoharringtonine trials recruiting patients?
Yes. 10 of the 17 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Homoharringtonine clinical trials?
Institute of Hematology & Blood Diseases Hospital, China (5), First Affiliated Hospital of Zhejiang University (5), baotai Liang (2) and Guangdong Second Provincial General Hospital (1), among 8 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Homoharringtonine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Homoharringtonine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Homoharringtonine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.